Is Sarepta’s Gene Therapy Elevidys Casting Doubt On A Popular DMD Endpoint?

 
• By Derrick Gingery
  
measuring tape
Will sponsors have to adjust the NSAA after Sarepta said the scale was not sensitive enough to detect patient changes? • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Cell & Gene Therapies

More from Advanced Technologies